Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, announces the availability of DecisionBase 10, an interactive decision tool that reveals the commercial opportunity of drugs in development and on the market and allows pharmaceutical and biotechnology organizations to compare those drugs with their own proprietary compounds. The unique database covers 35 diseases in a variety of therapeutic areas such as cardiovascular, central nervous system, oncology, immune and inflammatory disorders, infectious disease, psychiatric diseases, metabolic disorders, and other high-interest disease states.

  DecisionBase 10 allows users to perform the following forecasting tasks:    * Access information about and evaluate the potential for a specific drug     or disease.    * Drill down to a rich data set to understand current treatment and market     dynamics.    * Compare and contrast the unmet need and opportunity for proprietary     drug(s) against the future gold standard.  

New to DecisionBase 10 is the Target Product Profile methodology which outlines a commercially compelling drug development opportunity that is achievable within the next 10 to 15 years. Target Product Profiles are the most cost-effective way to measure physicians' future prescribing behaviors and builds profiles of realistic, impactful drugs. With a two-stage survey methodology, analysts uncover what physicians want to treat for a particular disease and then revisit physicians to have them determine what types of enhancements to a current drug are necessary to get them to change their prescribing habits.

"Target Product Profiles allow you to discover which drug attributes present the greatest threat to your established drugs as well as how to effectively enter a disease market with a new drug," said Sarah Fuller, president of Decision Resources. "The reports, available for the 35 indications covered in DecisionBase 10, include two comprehensive profiles for each disease. One explores the minimum improvement that physicians would be willing to accept for a new drug and the other uncovers what physicians would expect from a maximum achievement."

About DecisionBase 10

DecisionBase 10 is built on insights from leading published studies, interviews with hundreds of thought-leading physicians and researchers from seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), and input from Decision Resources' staff of therapeutic area experts. Its breadth of coverage, depth of analysis, and flexible modeling make DecisionBase an ideal tool for organizations looking to make strategic choices, model options, forecast potential, license new drugs, and achieve commercial success.

About Decision Resources

Decision Resources, Inc., ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Drugs From Bayer/Onyx and Pfizer Have Revolutionized the Renal Cell Carcinoma Treatment Market in the United States

View Now